{
    "clinical_study": {
        "@rank": "3003", 
        "brief_summary": {
            "textblock": "The goal of this pilot study is to determine if intra-arterial (IA) chemotherapy is safe in\n      the treatment of progressive diffuse intrinsic pontine gliomas (DIPG). IA administration of\n      the chemotherapeutic agent enhances the regional distribution of the drug, thereby\n      increasing the local delivered dose while minimizing systemic toxicity. It also provides a\n      treatment option for these patients at the time of tumor recurrence."
        }, 
        "brief_title": "Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).", 
        "condition": "Diffuse Intrinsic Pontine Glioma (DIPG)", 
        "condition_browse": {
            "mesh_term": [
                "Glioma", 
                "Pontine Glioma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Delivering the chemotherapeutic agent directly to the tumor via the arterial system avoids\n      the complications and adverse events associated with toxicity from systemic chemotherapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pediatric patients of all ages with progressive DIPG.\n\n          -  Consensus following presentation of the case at the multidisciplinary Pediatric\n             Neuro-Oncology conference, which includes participation of neuro-oncology,\n             neurosurgery, radiation oncology, interventional neuroradiology and neurology.\n\n        Exclusion Criteria:\n\n          -  Documented hypercoagulable disorders or vasculopathies\n\n               -  INR value more than a Grade 1 toxicity by CTCAE v 4.0 criteria (>1 -  1.5 x ULN;\n                  >1 - 1.5 times above baseline if on anticoagulation).\n\n               -  APTT value more than a Grade 1 toxicity by CTCAE v 4.0 criteria (>ULN - 1.5 x\n                  ULN).\n\n          -  Platelets less than 50 x 103/mm3\n\n          -  Absolute neutrophil count less than 500/ mm3\n\n          -  Pregnancy\n\n          -  Documented severe allergic reaction to IV iodinated contrast, specifically\n             bronchospasm and anaphylaxis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "1 Month"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01688401", 
            "org_study_id": "J11164", 
            "secondary_id": "NA_00069122"
        }, 
        "intervention": {
            "description": "Drug administered intra-arterially (injection in the artery).\nStandard dose: 6 mg, intra-arterial (IA) delivery.\nDuration of treatment: Eight weeks total - two cycles of IA chemotherapy, separated by four", 
            "intervention_name": "Melphalan hydrochloride", 
            "intervention_type": "Drug", 
            "other_name": "Alkeran"
        }, 
        "intervention_browse": {
            "mesh_term": "Melphalan"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "diffuse intrinsic pontine glioma (DIPG)", 
            "intra-arterial chemotherapy", 
            "angiography"
        ], 
        "lastchanged_date": "March 11, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21287"
                }, 
                "name": "The Johns Hopkins Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).", 
        "other_outcome": [
            {
                "description": "Analysis of immediate efficacy will be made by assessing for signs of tumor response as evidenced by a decrease in required steroid dose.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "description": "Analysis of immediate efficacy will be made by assessing for signs of tumor response as evidenced by a decrease in tumor size on MRI.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "description": "Analysis of immediate efficacy will be made by assessing for signs of tumor response as evidenced by a decrease in the degree of enhancement on MRI.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }, 
            {
                "description": "Analysis of immediate efficacy will be made by assessing for signs of tumor response as evidenced by an improved neurologic examination.", 
                "measure": "Efficacy", 
                "safety_issue": "No", 
                "time_frame": "60 days"
            }
        ], 
        "overall_official": {
            "affiliation": "The Johns Hopkins Hospital", 
            "last_name": "Monica Pearl, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "In this feasibility study, we are going to perform a qualitative evaluation of whether or not we can safely deliver IA chemotherapy to patients with progressive DIPG.\nAssessment of non-hematologic toxicity will include grading according to the Nervous system disorder CTCAE, specifically grades 3-5 intracranial hemorrhage and grades 3-5 stroke. Note will be made if the patient requires a blood transfusion.", 
            "measure": "Technical safety", 
            "safety_issue": "Yes", 
            "time_frame": "60 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01688401"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Analysis of long-term efficacy will be made by assessing progression free survival in terms of months.", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "Sidney Kimmel Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Solving Kids\u2019 Cancer", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Sidney Kimmel Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014", 
        "why_stopped": "Enrollment is on hold while study is under administrative review."
    }
}